Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail

Wed, 20th Mar 2024 18:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Transense Technologies PLC - Bicester, Oxfordshire-based developer of specialist sensor systems for vehicles - Appoints Ryan Maughan as managing director with immediate effect. Maughan joined Transense on a part-time basis as business development director of SAWsense on December 1 2021.

----------

ReNeuron Group PLC - Brigdend, Wales-based stem cell and exosomes technology company - Appoints Cork Gully LLP as administrators. Says talks with creditors to establish the solvency of the business, have taken place, with a particular focus on finding solutions that would allow the group to continue trading on a lower cost model. However, to date, these discussions have not progressed sufficiently to establish the precise solvency status of the business. Therefore, due to this increased financial uncertainty the decision has been taken to appoint administrators. Stresses discussions with potential investors, partners and creditors will remain open throughout the administration process.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - Updates on return of capital to shareholders. Says that the level of cash within the company's portfolio against the net asset value as at March 6 has increased to over 40%. Therefore, anticipates that it will be able to undertake an issue and redemption of B shares on or around April 4. This will enable a return capital of around 26.0 pence per share to shareholders. Says this is significantly improved on the previous anticipated return of around GBP10 million, or 21.5p per share.

----------

BAE Systems PLC - London-based defence, aerospace and security company - Announces private placement of notes to institutional buyers. Notes to be issued consist of USD800 million in aggregate principal amount of 5.000% notes due 2027, USD1.25 billion in aggregate principal amount of 5.125% notes due 2029, USD500 million in aggregate principal amount of 5.250% notes due 2031, USD1.50 billion in aggregate principal amount of 5.300% notes due 2034 and USD750 million in aggregate principal amount of 5.500% notes due 2054. Net proceeds will be used to refinance USD4.0 billion in aggregate principal amount outstanding under the bridge loan facility agreement incurred to fund part of the acquisition price of Ball Aerospace, and for general corporate purposes. Notes the offering is expected to close on or about March 26.

----------

Cloudbreak Discovery PLC - Vancouver, Canada-based natural resource project generator - Says Andrew Male and Paul Gurney have joined the Board of G2 Energy Ltd. Male is interim chief executive of Cloudbreak. Gurney is a non-executive director. Male states: "Paul and I look forward to working with G2 and their team in order to develop and enhance the production assets that G2 hold. Our primary focus will be to assist G2 in generating more revenue and looking at additional acquisitions that are accretive to the Cloudbreak investment and G2's underlying business operations."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 Jul 2010 07:27

ReNeuron Group To Present New Data Of Lead CTX Stem Cell Line

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN), a clinical-stage stem cell business, said Monday it will present important new data regarding the mechanisms of action of its lead CTX stem cell line in pre-clinical models of brain damage. MAIN FACTS: -The results of these studies will be pr

Read more
29 Jun 2010 07:51

ReNeuron Group FY Pretax Loss GBP6.2M On Revenue GBP31,000

LONDON (Dow Jones)--ReNeuron Group PLC (RENE.LN) said Tuesday that for the year ended March 31, it made a pretax loss of GBP6.2 million on revenue of GBP31,000. MAIN FACTS: -Revenue GBP31,000 (2009: GBP93,000) -Operating loss GBP6.2 million (2009: loss GBP4.7 million) -Pretax loss GB

Read more
28 Jan 2010 13:48

Sector movers: Drug sector off colour

The pharmaceuticals sector fell back after AstraZeneca posted a 10% rise in fourth quarter earnings, but predicted 2010 revenues would be hit by the loss of exclusive rights to sell certain drugs. The company is also planning to cut 8,000 jobs from its global workforce of 63,000. While Astra falls

Read more
28 Jan 2010 11:25

Small caps round-up: Xcite, ReNeuron, CPL Resources

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea. ReNeuron group climbed after the stem cell developer said Pha

Read more
11 Jan 2010 16:41

London close: Footsie gives up gains

The leading share index gave up early gains to finish only slightly higher as euphoria over strong trade figures from China in December gave way to renewed fears over recovery prospects. China's December imports jumped by 55.9% from the same month the previous year, while exports were 17.7% higher

Read more
11 Jan 2010 14:16

London afternoon: Stocks back on the climb

Leading shares, which had been surrendering early gains at the end of the morning, picked up again over the lunch time session, helped by expectations of a firm start by Wall Street. In the absence of much in the way of corporate events to attract attention, traders have been focused on broker note

Read more
11 Jan 2010 08:44

ReNeuron poised for stroke treatment trials

Stem cell therapy group ReNeuron said it is on track to start human trials of its flagship treatment ReN001 for disabled stroke patients in the first quarter of this year. ReNeuron said it has submitted extra data for the UK's Gene Therapy Advisory Committee. If a successful review of the data is r

Read more
26 Nov 2009 14:45

Small caps round-up: Hampson Industries, Bezant, Tangent Comms...

Aerospace and engineering group Hampson Industries reported a 32% slump in first half profit before tax to £11m on revenue down 12% to £97m. "Although the immediate outlook for our core markets remains uncertain, present customer indications and the scale of new work in the pipeline all point to a

Read more
16 Nov 2009 11:54

Small caps round-up: Ocean Wilsons, Fortune Oil, Freshwater...

PR and marketing group Freshwater's profits fell sharply last year, but the fourth quarter saw an improvement that has continued into the current year. Pre-tax profit fell to £0.24m from £1.17m, on sales of £9.1m down from £9.5m. "Profitability improved in the second half, and we have gone into th

Read more
2 Oct 2009 15:33

ReNeuron boosted by study findings

Shares in stem cell developer ReNeuron were wanted after the company drew attention to the publication of new research using the company's ReNcell neural stem cell products. Researchers based in California have developed a safe strategy for reprogramming cells to a pluripotent (capable of affecting

Read more
17 Sep 2009 08:39

Small caps round-up: Byotrol, ReNeuron, Accuma...

Germ-killing product supplier Byotrol said it has seen a significant increase in orders and now expects results for the financial year to September 30 to be ahead of expectations. Shares in Meridian Petroleum gushed higher after the oil and gas firm announced an increase in prospective resources in

Read more
8 Jul 2009 13:44

Sector movers: Astra lifts drug stocks after broker boost

Pharmaceutical stocks are higher after the broker Panmure Gordon said AstraZeneca was set to benefit from US rivals that produce generic alternatives to its cancer drug Casodex being too slow off the mark. AstraZeneca's slight rise is not as impressive as that of stem cell therapy developer ReNeuro

Read more
8 Jul 2009 10:55

Small caps round-up: Brainjuicer, ReNeuron, Hamworthy...

Market researcher BrainJuicer, whose clients include Unilever and Nike, posted revenue growth of about 22% for the first half and said it expects to make further progress in 2009. Stem cell therapy developer ReNeuron said clinical data on its lead CTX neural stem cell line in stroke and neurodegene

Read more
30 Jun 2009 09:00

Small caps round-up: MediaZest, Reneuron, Atlantic Coal...

Display advertising and screens provider Mediazest's pre-tax profits slide in the year as administrative expenses were too high, prompting the firm to undertake further cost cutting measures. The group also said first half of 2009 has seen a drop in activity as a consequence of the economic downt

Read more
9 Jun 2009 12:21

Angel rallies on ReNeuron deal

Angel Biotechnology rallied on news that the biopharmaceutical contract manufacturer signed a GMP manufacturing deal with ReNeuron. The value of the contract was not disclosed. The signing of deal follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.